Publication:
Viral Kinetics in Semen With Different Antiretroviral Families in Treatment-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Trial

dc.contributor.authorGutierrez-Valencia, Alicia
dc.contributor.authorBenmarzouk-Hidalgo, Omar J.
dc.contributor.authorRivas-Jeremias, Inmaculada
dc.contributor.authorEspinosa, Nuria
dc.contributor.authorTrujillo-Rodriguez, Maria
dc.contributor.authorFernandez-Magdaleno, Tamara
dc.contributor.authorViciana, Pompeyo
dc.contributor.authorLopez-Cortes, Luis F.
dc.contributor.authoraffiliation[Gutierrez-Valencia, Alicia] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain
dc.contributor.authoraffiliation[Benmarzouk-Hidalgo, Omar J.] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain
dc.contributor.authoraffiliation[Rivas-Jeremias, Inmaculada] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain
dc.contributor.authoraffiliation[Espinosa, Nuria] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain
dc.contributor.authoraffiliation[Trujillo-Rodriguez, Maria] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain
dc.contributor.authoraffiliation[Fernandez-Magdaleno, Tamara] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain
dc.contributor.authoraffiliation[Viciana, Pompeyo] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain
dc.contributor.authoraffiliation[Lopez-Cortes, Luis F.] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain
dc.contributor.funderGilead Science
dc.date.accessioned2023-02-12T02:21:22Z
dc.date.available2023-02-12T02:21:22Z
dc.date.issued2017-08-15
dc.description.abstractBackground. There are several regimens for starting antiretroviral treatment, but it remains unknown whether either of them is more advantageous regarding the time course and magnitude of human immunodeficiency virus (HIV) RNA decay in semen.Objective. To evaluate the differential effect of different antiretroviral drug families on viral kinetics in seminal plasma (SP) of treatment-naive HIV-infected patients.Methods. Phase II, randomized, open-label study in which participants were randomized 1: 1: 1 to receive tenofovir-disoproxil fumarate (DF) plus emtricitabine, and either cobicistat-boosted elvitegravir (EVG(cobi)), rilpivirine (RPV), or ritonavir-boosted darunavir (DRVrtv). The primary endpoint was the proportion of participants with undetectable HIV-RNA in SP at week 12. HIV type 1 (HIV-1) RNA was measured in paired SP and blood plasma (BP) at baseline and after 1, 2, 4, 6, 8, 12, 18, and 24 weeks. Elvitegravir (EVG), RPV, and darunavir (DRV) concentrations were quantified by the liquid chromatography-tandem mass spectrometry method.Results. In SP, the HIV-RNA decay rate with RPV was as fast as with EVG(cobi); by week 12, all participants in the RPV and the EVG(cobi) groups reached an undetectable viral load but only 58.3% in the DRVrtv arm (P = .003). The highest SP/BP drug concentration ratio was for EVG (0.43), followed-up by RPV (0.19), and DRV (0.10). For both EVG and RPV, the SP concentrations exceeded >2-fold the protein binding-adjusted EC90 for wild-type HIV-1; for DRV, only 33.7% of the SP showed concentrations above the protein binding-adjusted EC90.Conclusions. In SP, both RPV and EVG(cobi), associated to tenofovir-DF and emtricitabine, behave similarly and achieve an undetectable viral load much faster than DRVrtv.
dc.identifier.doi10.1093/cid/cix358
dc.identifier.essn1537-6591
dc.identifier.issn1058-4838
dc.identifier.unpaywallURLhttps://academic.oup.com/cid/article-pdf/65/4/551/19378720/cix358.pdf
dc.identifier.urihttp://hdl.handle.net/10668/18939
dc.identifier.wosID406670800004
dc.issue.number4
dc.journal.titleClinical infectious diseases
dc.journal.titleabbreviationClin. infect. dis.
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number551-556
dc.publisherOxford univ press inc
dc.rights.accessRightsopen access
dc.subjectHIV-1
dc.subjectsemen
dc.subjectmale genital tract
dc.subjectantiretroviral treatment
dc.subjectCo-formulated elvitegravir
dc.subjectHiv-1 rna
dc.subjectInitial treatment
dc.subjectDouble-blind
dc.subjectWild-type
dc.subjectRilpivirine
dc.subjectBlood
dc.subjectEmtricitabine
dc.subjectDolutegravir
dc.subjectCompartments
dc.titleViral Kinetics in Semen With Different Antiretroviral Families in Treatment-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Trial
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number65
dc.wostypeArticle
dspace.entity.typePublication

Files